David Linden, MD
Psychiatry · Las Vegas, NVNPI 1821062324
Payments from drug & device makers
Across 508 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Vanda Pharmaceuticals Inc.$2K
- Johnson & Johnson$933
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$874
- Alkermes, Inc.$691
- E.r. Squibb & Sons, L.L.C.$470
- plus $4K from 21 others
What the payments were for
- Food & beverage$10,24699%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 123 | $1,943 |
| Vanda Pharmaceuticals Inc. | 68 | $1,712 |
| Johnson & Johnson | 48 | $933 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $874 |
| Alkermes, Inc. | 31 | $691 |
| E.r. Squibb & Sons, L.L.C. | 19 | $470 |
| Lundbeck LLC | 24 | $408 |
| Neurocrine Biosciences, Inc. | 10 | $384 |
| AbbVie(2 entities) | 27 | $380 |
| Teva Pharmaceuticals USA, Inc. | 22 | $375 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $323 |
| Supernus Pharmaceuticals, Inc. | 20 | $271 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $212 |
| Almatica Pharma LLC | 11 | $199 |
| Neuronetics, Inc. | 2 | $192 |
| Eisai Inc. | 8 | $148 |
| Avanir Pharmaceuticals, Inc. | 5 | $109 |
| Forte Bio-pharma LLC | 5 | $100 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Sunovion Pharmaceuticals Inc. | 6 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Itamar Medical Inc | 1 | $23 |
| Merck | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$175
- COBENFY$131
- SPRAVATO$123
- CAPLYTA$118
- NEUROSTAR TMS THERAPY SYSTEM$115
- ABILIFY MAINTENA$110
How this compares
$10,333 in reported general payments places this provider in the 90th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 15 | $20,129 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,991 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,878 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 151 | $5,536 |
| Topiramate ErTopiramate | 12 | $5,130 |
| Aripiprazole | 240 | $4,832 |
| Hydroxyzine Hcl | 215 | $3,724 |
| Alprazolam | 649 | $3,694 |
| Bupropion XlBupropion Hcl | 287 | $2,821 |
| Clomipramine Hcl | 51 | $2,766 |
| Quetiapine Fumarate | 168 | $2,405 |
| Duloxetine Hcl | 169 | $2,008 |
| Mirtazapine | 188 | $1,669 |
| Buspirone Hcl | 155 | $1,614 |
| Paroxetine Hcl | 139 | $1,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,943 | $20,12915 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $109 | $17,99112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $323 | $6,87814 claims |
| Almatica Pharma LLCSertraline Hcl | $199 | $628132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$12.4M
- Mustafa RawafLas Vegas$5.1M
- Aaron RitterLas Vegas$2.7M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Dylan WintLas Vegas$272K
- Akindele KoladeLas Vegas$79K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.